D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 79 Citations 30,480 263 World Ranking 10189 National Ranking 5449

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Gene

The scientist’s investigation covers issues in Cancer research, Immunology, Internal medicine, Pathology and Cancer. His Cancer research research incorporates themes from Cancer cell and Immunotherapy. His Immunology research includes themes of Blood vessel and CD34.

His Internal medicine study integrates concerns from other disciplines, such as Brain tumor, Endocrinology and Oncology. His Pathology study combines topics in areas such as Vascular endothelial growth factor A, Extracellular matrix and In vivo. His study in Cancer is interdisciplinary in nature, drawing from both Bevacizumab and Intravital microscopy.

His most cited work include:

  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (1739 citations)
  • AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients (1520 citations)
  • Angiogenesis in brain tumours (995 citations)

What are the main themes of his work throughout his whole career to date?

Dan G. Duda spends much of his time researching Internal medicine, Cancer research, Oncology, Cancer and Pathology. His study connects Endocrinology and Internal medicine. Dan G. Duda has included themes like Cancer cell, Metastasis and Immunology in his Cancer research study.

His Oncology study incorporates themes from Breast cancer, Clinical endpoint, Clinical trial and Chemotherapy. The concepts of his Pathology study are interwoven with issues in Endothelial stem cell, Stem cell and Myeloid. Dan G. Duda interconnects Neoadjuvant therapy, Colorectal cancer, Radiation therapy and Perfusion in the investigation of issues within Bevacizumab.

He most often published in these fields:

  • Internal medicine (40.40%)
  • Cancer research (35.24%)
  • Oncology (30.66%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (40.40%)
  • Oncology (30.66%)
  • Cancer research (35.24%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Internal medicine, Oncology, Cancer research, Hepatocellular carcinoma and Cancer. Dan G. Duda studied Internal medicine and Gastroenterology that intersect with Growth factor. His studies deal with areas such as Bevacizumab, Chemotherapy, Cabozantinib and Angiogenesis as well as Oncology.

His study in Cancer research is interdisciplinary in nature, drawing from both Blockade, Immune system, Immunotherapy, Breast cancer and PI3K/AKT/mTOR pathway. His work deals with themes such as Radiation therapy and VEGF receptors, which intersect with Immune system. Dan G. Duda works on Cancer which deals in particular with Cancer cell.

Between 2016 and 2021, his most popular works were:

  • Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. (375 citations)
  • Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma (247 citations)
  • Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? (196 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His primary areas of study are Cancer research, Internal medicine, Oncology, Cancer and Immunotherapy. Dan G. Duda has included themes like Cancer cell, Blockade, Breast cancer and Immune system in his Cancer research study. His Internal medicine study frequently intersects with other fields, such as Gastroenterology.

His research in Oncology intersects with topics in Bevacizumab, Nivolumab and Angiogenesis. His research integrates issues of Cell, Everolimus and Chemotherapy in his study of Cancer. Within one scientific family, Dan G. Duda focuses on topics pertaining to Immunosuppression under Immunotherapy, and may sometimes address concerns connected to Atezolizumab.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda.
Nature Medicine (2004)

2335 Citations

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Tracy T. Batchelor;A. Gregory Sorensen;A. Gregory Sorensen;Emmanuelle di Tomaso;Wei Ting Zhang;Wei Ting Zhang.
Cancer Cell (2007)

1943 Citations

Angiogenesis in brain tumours

Rakesh K. Jain;Emmanuelle di Tomaso;Dan G. Duda;Jay S. Loeffler.
Nature Reviews Neuroscience (2007)

1319 Citations

NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES

Shom Goel;Dan G. Duda;Lei Xu;Lance L. Munn.
Physiological Reviews (2011)

1286 Citations

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

Rakesh K Jain;Dan G Duda;Jeffrey W Clark;Jay S Loeffler.
Nature Reviews Clinical Oncology (2006)

1280 Citations

Engineering vascularized tissue

Rakesh K Jain;Patrick Au;Josh Tam;Dan G Duda.
Nature Biotechnology (2005)

765 Citations

Biomarkers of response and resistance to antiangiogenic therapy.

Rakesh K. Jain;Dan G. Duda;Christopher G. Willett;Dushyant V. Sahani.
Nature Reviews Clinical Oncology (2009)

614 Citations

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Yuhui Huang;Jianping Yuan;Elda Righi;Walid S. Kamoun.
Proceedings of the National Academy of Sciences of the United States of America (2012)

587 Citations

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

Christopher G. Willett;Dan G. Duda;Emmanuelle di Tomaso;Yves Boucher.
Journal of Clinical Oncology (2009)

558 Citations

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Andrew X. Zhu;Dushyant V. Sahani;Dan G. Duda;Emmanuelle di Tomaso.
Journal of Clinical Oncology (2009)

530 Citations

Best Scientists Citing Dan G. Duda

Rakesh K. Jain

Rakesh K. Jain

Harvard University

Publications: 147

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 112

David A. Reardon

David A. Reardon

Harvard University

Publications: 63

Dai Fukumura

Dai Fukumura

Harvard University

Publications: 61

Peter Carmeliet

Peter Carmeliet

KU Leuven

Publications: 59

Andrew X. Zhu

Andrew X. Zhu

Harvard University

Publications: 59

Josep M. Llovet

Josep M. Llovet

Icahn School of Medicine at Mount Sinai

Publications: 57

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 53

Tracy T. Batchelor

Tracy T. Batchelor

Brigham and Women's Hospital

Publications: 51

Robert S. Kerbel

Robert S. Kerbel

Sunnybrook Health Science Centre

Publications: 47

Michael Weller

Michael Weller

University of Zurich

Publications: 45

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 43

Ann-Lii Cheng

Ann-Lii Cheng

National Taiwan University

Publications: 38

adrian l harris

adrian l harris

University of Oxford

Publications: 37

Napoleone Ferrara

Napoleone Ferrara

University of California, San Diego

Publications: 37

Jeremy N. Rich

Jeremy N. Rich

University of Pittsburgh

Publications: 36

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.